- INMAZEB must be administered by a healthcare provider.
- Allow the diluted infusion solution to come to room temperature prior to administration.
- INMAZEB diluted with 5% Dextrose Injection, USP can be infused at temperatures up to 35°C (95°F). When the temperature is higher than 25°C (77°F), administer the diluted INMAZEB with 5% Dextrose Injection, USP immediately after completion of dose preparation.
- Administer the diluted infusion solution intravenously through an intravenous line containing a sterile, in-line or add-on 0.2-micron filter.
- The infusion rate is based on the patient's body weight and prepared infusion volume. Select an appropriate infusion rate for the diluted infusion solution (see Table 2). It is important to follow the infusion time outlined in Table 2 based on the patient's weight.
- The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events [see Warnings and Precautions (5.1)].
- Do not mix other medications with INMAZEB.
- Compatibility studies of INMAZEB have not been performed when co-administering other drugs simultaneously through the same infusion line.
Discontinuation and Infusion Rate Adjustments in the PALM Trial
Approximately 99% of subjects who received INMAZEB in the PALM trial were able to complete their dose within three hours. Two subjects who received INMAZEB (1%) did not receive their complete infusion. One of the two subjects did not complete their INMAZEB infusion because of fever elevation [see Warnings and Precautions (5.1)].
Selected Laboratory Abnormalities in the PALM Trial
Table 5 presents selected laboratory abnormalities (worsening to Grade 3 or 4 compared to baseline) for adult and pediatric subjects in the PALM trial.
Table 5: Selected Grade 3 and 4 Laboratory Abnormalities, Worsened Grade from Baseline for Adult and Pediatric Subjects in the PALM Trial| Laboratory Test Graded per Division of AIDS (DAIDS) v2.1 | INMAZEB N=154 % | Control N=168 % |
|---|
| ULN = upper limit of normal |
| Sodium, high ≥ 154 mmol/L | 9 | 4 |
| Sodium, low < 125 mmol/L | 7 | 11 |
| Potassium, high ≥ 6.5 mmol/L | 13 | 12 |
| Potassium, low < 2.5 mmol/L | 9 | 8 |
| Creatinine (mg/dL) ≥ 1.8 × ULN ULN for creatinine was 1.2 mg/dL. Criterion for increase to ≥ 1.5 × from baseline was applied if the worsening grade was higher. | 15 | 23 |
| Alanine aminotransferase (U/L) ≥ 5 × ULN | 10 | 14 |
| Aspartate aminotransferase (U/L) ≥ 5 × ULN | 21 | 18 |
Risk Summary
Orthoebolavirus zairense infection is life-threatening for both the mother and fetus and treatment should not be withheld due to pregnancy (see Clinical Considerations). Available data from the PALM trial and an expanded access program in which pregnant women with Orthoebolavirus zairense infection were treated with INMAZEB demonstrate the high rate of maternal and fetal/neonatal morbidity consistent with published literature regarding the risk associated with underlying maternal Orthoebolavirus zairense infection. These data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome. Animal reproduction studies with INMAZEB have not been conducted. Human monoclonal antibodies, such as INMAZEB, are transported across the placenta; therefore, INMAZEB has the potential to be transferred from the mother to the developing fetus.
Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Maternal, fetal and neonatal outcomes are poor among pregnant women infected with Orthoebolavirus zairense. The majority of such pregnancies result in maternal death with miscarriage, stillbirth, or neonatal death. Treatment should not be withheld due to pregnancy.
Risk Summary
The Centers for Disease Control and Prevention recommend that patients with confirmed Orthoebolavirus zairense not breastfeed their infants to reduce the risk of postnatal transmission of Orthoebolavirus zairense infection.
There are no data on the presence of atoltivimab, maftivimab, and odesivimab-ebgn in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to atoltivimab, maftivimab, or odesivimab-ebgn are unknown.
Specific Populations
The effect of age (< 21 or > 60), renal impairment, or hepatic impairment on the pharmacokinetics of atoltivimab, maftivimab, and odesivimab is unknown.
Mechanism of Action
INMAZEB is a combination of three recombinant human IgG1κ monoclonal antibodies each targeting the Orthoebolavirus zairense glycoprotein (EBOV GP). Orthoebolavirus zairense (EBOV) encodes a sole envelope protein, the glycoprotein, which mediates virus attachment and membrane fusion with the host cell membranes. In addition, GP is expressed on the surface of Orthoebolavirus zairense infected host cells making it a target for antibodies that can mediate killing of these cells by antibody dependent cellular cytotoxicity and/or other effector functions. The 3 antibodies that make up the combination bind to 3 non-overlapping epitopes on GP and all 3 antibodies can bind the GP simultaneously. The mean KD values for atoltivimab, maftivimab, and odesivimab were 7.84 nM, 3.34 nM, and 8.26 nM, respectively, as determined by surface plasmon resonance. Maftivimab is a neutralizing antibody that blocks entry of the virus into susceptible cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcyRIIIa signaling when bound to its target. Odesivimab also binds to the soluble form of Orthoebolavirus zairense glycoprotein (sGP). Atoltivimab combines both neutralization and FcyRIIIa signaling activities.
Antiviral Activity
In a live virus infection assay on Vero cells, maftivimab neutralized Mayinga, Kikwit, and Makona strains of Orthoebolavirus zairense, with a concentration between 0.2 and 1.2 nM (0.03 and 0.18 μg/mL) providing 80% inhibition of viral infection in a plaque-reduction neutralization test (PRNT-80). Atoltivimab and odesivimab did not demonstrate any neutralizing activity in this assay. Effector function activity of INMAZEB individual antibodies was assessed with an EBOV Makona-GP expressing cell line and Jurkat/NFAT-Luc/FcγRIIIa reporter effector cells. The EC50 values of atoltivimab and odesivimab were 2.9 nM and 1.6 nM, respectively, whereas maftivimab did not exhibit any FcγRIIIa signaling activity at the maximum concentration tested, 40 nM.
Treatment of Orthoebolavirus zairense infected rhesus macaques with a single intravenous dose of INMAZEB (50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg) generally protected infected animals from Orthoebolavirus zairense mediated death when drug was administered 5 days post-infection.
Resistance
No clinical data are available on the development of EBOV resistance to INMAZEB. Previously identified substitutions in EBOV were assessed for activity in binding, neutralization and ADCC. Results of these assays are presented in Table 7, Table 8, and Table 9. The clinical significance of these substitutions is unknown.
Binding Activity
Binding was assessed with an electrochemiluminescence (ECL)-based assay using virus like particles (VLPs) pseudotyped with EBOV Makona 2014 reference GP or variant EBOV GP. The results of this assay are shown in Table 7.
Table 7: Summary of Reduced Binding of Atoltivimab, Odesivimab, Maftivimab and INMAZEB to VLPs Pseudotyped with EBOV GP Variants Compared to EBOV Makona 2014 GP Reference| Orthoebolavirus zairense Variant | Reduced Binding Activity of Atoltivimab Alone | Reduced Binding Activity of Odesivimab Alone | Reduced Binding Activity of Maftivimab Alone | Reduced Binding Activity of INMAZEB |
|---|
| P34S | NC NC, no change: <5.1-fold reduction in binding activity compared to EBOV Makona 2014 reference GP. A <5.1-fold change in EC50 value is within the inherent variability of this assay. However, the <5.1 fold-change threshold cannot rule out the possibility that substitutions that lead to fold-changes below this threshold have a meaningful impact on binding. The clinical significance of a ≥ 5.1-fold reduction in binding activity is unknown | NC | NC | NC |
| N40D | NC | NC | NC | NC |
| T144M | NC | ≥9-fold Where an EC50 value could not be accurately calculated, the change in mAb potency in the presence of each mutant was calculated by dividing the maximum antibody concentration tested (333nM) by the EC50 value calculated for atoltivimab, odesivimab, maftivimab, and INMAZEB in the presence of reference VLP | NC | NC |
| P209T | NC | NC | NC | NC |
| Q221K | NC | NC | NC | NC |
| G224D | NC | ≥9-fold | NC | NC |
| L239S | NC | NC | NC | NC |
| K265M | NC | NC | NC | NC |
| G271E | NC | NC | NC | NC |
| L273P | NC | NC | NC | NC |
| I274M | NC | NC | NC | NC |
| W275L | NC | NC | NC | NC |
| E280G | >186-fold | Nc | NC | NC |
| E304A | NC | NC | NC | NC |
| S347F | NC | NC | NC | NC |
| R501G | NC | NC | NC | NC |
| A507S | NC | NC | NC | NC |
| A507T | NC | NC | NC | NC |
| I527T | NC | NC | NC | NC |
| G528R | NC | NC | ≥454-fold | NC |
| F535L | NC | NC | NC | NC |
| T544I | NC | NC | NC | NC |
| H549R | NC | NC | NC | NC |
| N563T | NC | NC | >454-fold | NC |
| E564A | NC | NC | NC | NC |
| E564K | NC | NC | >454-fold | NC |
| K588N | NC | NC | NC | NC |
Neutralization Activity
Neutralization by atoltivimab, maftivimab, and INMAZEB was assessed using VLPs pseudotyped with EBOV Makona 2014 reference GP or variant EBOV GP. Odesivimab did not demonstrate any neutralizing activity in this assay. The results of this assay are shown in Table 8.
Table 8: Summary of Reduced VLP Neutralizing Activities of Atoltivimab, Maftivimab and INMAZEBA fold reduction in neutralization activity for odesivimab could not be calculated because concentration-dependent activity was not observed within the tested range of concentrations
| Orthoebolavirus zairense Variant | Reduced Neutralizing Activity of Atoltivimab Alone | Reduced Neutralizing Activity of Maftivimab Alone | Reduced Neutralizing Activity of INMAZEB |
|---|
| P34S | NC NC, no change: <4.3-fold reduction in neutralization activity compared to EBOV Makona 2014 reference GP. A <4.3-fold change in EC50 value is within the inherent variability of this assay. However, the <4.3 fold-change threshold cannot rule out the possibility that substitutions that lead to fold-changes below this threshold have a meaningful impact on neutralization. The clinical significance of a ≥ 4.3-fold reduction in neutralization activity is unknown | NC | NC |
| N40D | NC | NC | NC |
| T144M | NC | NC | NC |
| P209T | NC | NC | NC |
| Q221K | NC | NC | NC |
| G224D | NC | NC | NC |
| L239S | NC | NC | NC |
| K265M | >506-fold | NC | NC |
| G271E | NC | NC | NC |
| L273P | >506-fold | NC | NC |
| I274M | NC | NC | NC |
| W275L | >170-fold Where an EC50 value could not be accurately calculated, the change in mAb potency in the presence of each mutant was calculated by dividing the maximum antibody concentration tested (66.67nM) by the EC50 value calculated for REGN3470, REGN3471, REGN3479, and REGEN-EB3 in the presence of reference VLP | NC | NC |
| E280G | >445-fold | 6-fold | 9-fold |
| E304A | >506-fold | NC | NC |
| S347F | NC | NC | NC |
| R501G | NC | NC | NC |
| A507S | NC | NC | NC |
| A507T | NC | NC | NC |
| I527T | NC | NC | NC |
| G528R | NC | >81-fold | NC |
| F535L | NC | NC | NC |
| T544I | NC | NC | NC |
| H549R | NC | NC | NC |
| N563T | NC | >81-fold | NC |
| E564A | NC | 38-fold | 5-fold |
| E564K | 5-fold | >451-fold | 6-fold |
| K588N | NC | NC | NC |
Antibody-dependent Cellular Cytotoxicity
The potential to mediate antibody-dependent cellular cytotoxicity (ADCC) was assessed using a surrogate ADCC reporter bioassay measuring FCGR3A signaling. Maftivimab did not demonstrate any ADCC activity in this assay. The results of this assay are shown in Table 9.
Table 9: Summary of Reduced ADCC Activities of Atoltivimab, Odesivimab, and INMAZEBA fold reduction in ADCC activity for maftivimab and antibody responses to select variants could not be calculated because concentration-dependent activity was not observed within the tested range of concentrations
| Orthoebolavirus zairense Variant | Reduced ADCC Activity of Atoltivimab | Reduced ADCC activity of Odesivimab | Reduced ADCC activity of INMAZEB |
|---|
| P34S | NC NC, no change: <2.9-fold reduction in ADCC activity compared to EBOV Makona 2014 reference GP. A <2.9-fold change in ADCC activity is within the inherent variability of this assay. However, the <2.9 fold-change threshold cannot rule out the possibility that substitutions that lead to fold-changes below this threshold have a meaningful impact on ADCC activity. The clinical significance of a ≥ 2.9-fold reduction in ADCC activity is unknown | NC | NC |
| N40D | NC | NC | NC |
| T144M | NC | >59-fold Where an EC50 value could not be accurately calculated, fold change in EC50 in the presence of each mutant was calculated by dividing the maximum antibody concentration tested (100nM) by the EC50 value calculated for REGN3470, REGN3471 with ADCC activity obtained with target cells expressing reference EBOV GP (EBOV Makona 2014) | NC |
| P209T | NC | 4-fold | NC |
| Q221K | NC | 3-fold | NC |
| G224D | NC | >59-fold | NC |
| L239S | NC | 5-fold | 3-fold |
| K265M | 65-fold | 6-fold | 28-fold |
| G271E | NC | 24-fold | NC |
| L273P | 10-fold | 6-fold | 19-fold |
| I274M | NC | NC | 6-fold |
| W275L | 25-fold | NC | 8-fold |
| E280G | >237-fold | NC | 6-fold |
| E304A | NC | NC | NC |
| S347F | NC | 3-fold | NC |
| R501G | NC | NC | NC |
| A507S | NC | 12-fold | NC |
| A507T | NC | 10-fold | NC |
| I527T | NC | 6-fold | NC |
| G528R | NC | NC | NC |
| F535L | NC | 8-fold | NC |
| T544I | NC | NC | NC |
| H549R | NC | 7-fold | 4-fold |
| N563T | NC | NC | NC |
| E564A | NC | NC | NC |
| E564K | NC | NC | NC |
| K588N | NC | NC | NC |
Immune Response
Interaction studies with recombinant live EBOV vaccines and INMAZEB have not been conducted [see Drug Interactions (7.1)].
Hypersensitivity Reactions Including Infusion-Associated Events
Inform patients that hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB and to immediately report if they experience any symptoms of systemic hypersensitivity reactions [see Warnings and Precautions (5.1)].
Lactation
Instruct patients with Orthoebolavirus zairense infection not to breastfeed because of the risk of passing Orthoebolavirus zairense to the baby [see Use in Specific Populations (8.2)].
Manufactured by:
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
U.S. License No. 1760
INMAZEB is a registered trademark owned by Regeneron Pharmaceuticals, Inc.
©2024 Regeneron Pharmaceuticals, Inc. All rights reserved.